Chemistry:GSK 299423
From HandWiki
| Names | |
|---|---|
| Preferred IUPAC name
6-Methoxy-4-[2-(4-{[(2H-[1,3]oxathiolo[5,4-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)ethyl]quinoline-3-carbonitrile | |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C25H27N5O2S | |
| Molar mass | 461.58 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |

GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.[1][2][3]
No animal studies have been reported. No application has been made for human clinical trials.[citation needed]
References
- ↑ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria[yes|permanent dead link|dead link}}]," The Wall Street Journal , August 4, 2010
- ↑ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' " Daily Finance, August 6, 2010
- ↑ "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature 466 (7309): 935–40. 4 August 2010. doi:10.1038/nature09197. PMID 20686482. Bibcode: 2010Natur.466..935B. (primary source)
